Skip to main content

Table 3 pCR analyses in the ITT populations

From: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

  P013 Reference pertuzumab Difference (95% Confidence interval)
Total pCR (ITT) 60 (56.07) 68 (63.55) −0.07 (− 0.21, 0.06)
  1. For ITT analysis, patients with missing assessments were considered to be nonresponders
  2. Difference = P013- Reference pertuzumab
  3. pCR Pathological complete response